CLINUVEL Unveils Future of Photomedicine and PhotoCosmetics at Exclusive Event Hosted by Lady Gaga: In a remarkable gathering at Lady Gaga and Michael Polansky’s Malibu residence, leading biotech company CLINUVEL took center stage, showcasing its groundbreaking melanocortin therapies that are reshaping the landscape of photomedicine. The intimate event, co-hosted by Sean Parker and Alexandra Parker, celebrated CLINUVEL’s transformative work in addressing photodamage and skin cancer risks among patients globally.
CLINUVEL, a global biopharmaceutical firm, has been at the forefront of developing cutting-edge melanocortin therapies. The event served as a platform to highlight the company’s pivotal role in revolutionizing healthcare, with a focus on patients at the highest risk of light-related conditions.
The hosts, Lady Gaga, Michael Polansky, Sean Parker, and Alexandra Parker, shared their enduring support for CLINUVEL, spanning over 15 years. They drew parallels between the company’s pioneering medical approach and the boundary-pushing initiatives of the Parker Institute for Cancer Immunotherapy, which aims to transform the landscape of healthcare.
During the event, guests enjoyed a family-style dinner prepared by renowned chef Evan Funke of Felix Trattoria, complemented by a captivating performance by the Grammy-winning Attacca Quartet. CLINUVEL’s CEO, Dr. Philippe Wolgen, took the opportunity to unveil the company’s future endeavors in the dynamic field of photomedicine.
Over the past 25 years, CLINUVEL has pioneered melanocortin therapies, addressing the needs of patients overlooked by the pharmaceutical industry. This includes groundbreaking treatments for genetic disorders like erythropoietic protoporphyria (EPP), xeroderma pigmentosum (XP), and the pigmentation disorder vitiligo.
Now, CLINUVEL is poised to explore the expansive potential of its melanocortin technology, seeking to scale up its unique knowledge to address widespread health conditions affecting the skin, brain, and nervous system. Additionally, after 43 years of photomedicine research, CLINUVEL is set to disrupt the skincare market with the launch of PhotoCosmetics, an advanced skincare product range based on melanocortin peptides.
At the heart of the event’s philanthropic focus, CLINUVEL announced the creation of the Photomedicine Foundation. Michael Polansky will serve as a trustee for this initiative, which aims to extend CLINUVEL’s expertise directly to communities unable to afford care or treatment. The foundation’s mission is to support vulnerable patients at extreme risk of photodamage and skin cancer in Africa, the Middle East, and Latin America, aligning with the passion for long-lasting change shared by Lady Gaga, Michael Polansky, Sean Parker, and Alexandra Parker.
